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Abstract Phosphoglucose isomerase (PGI) is a cytosolic gly-
colytic enzyme that also functions as an extracellular cytokine
(neuroleukin/autocrine motility factor (AMF)/maturation fac-
tor). Contrary to mammalian PGI, bacterial PGI was not in-
ternalized by the PGI/AMF receptor (gp78/AMF-R) and nei-
ther bacterial nor yeast PGI competed with mammalian PGI for
receptor binding and internalization. Furthermore, while the
bacterial, yeast and mammalian preparations all exhibited iso-
merase activity, only mammalian PGI stimulated the motility of
NIH-3T3 ¢broblasts. The conserved active site of PGI is there-
fore not su⁄cient for receptor binding and cytokine activity of
PGI. However, synthetic peptides corresponding to distinct pe-
ripheral mammalian PGI sequences did not inhibit internaliza-
tion of mammalian PGI. Our data therefore argue that the
cytokine activity of PGI is speci¢c to mammalian PGI but
cannot exclude the possibility that the receptor binding motif
of PGI is complex and includes elements within and without the
active site. 1 2002 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
Phosphoglucose isomerase (PGI, EC 5.3.1.9) is an essential
cytosolic enzyme expressed in all tissues that catalyzes the
conversion of D-glucose 6-phosphate and D-fructose 6-phos-
phate. It plays an essential role in glycolysis and gluconeo-
genesis. An extracellular cytokine function for PGI has also
been identi¢ed and the PGI polypeptide sequence is identical
to that of autocrine motility factor (AMF), neuroleukin and
maturation factor [1^4]. PGI (or neuroleukin) increases the
survival of cultured sensory neurons and is secreted by lec-
tin-stimulated T-cells and induces maturation of B-cells into
antibody secreting cells [5,6]. As maturation factor, PGI has
been shown to induce the di¡erentiation of human myeloid
cells into monocytes [4]. PGI has also been shown to be in-
volved in osteoblast di¡erentiation during mineralization [7].
As AMF, PGI was identi¢ed as a cytokine secreted by tumor
cells whose expression is linked to tumor cell invasion and
metastasis [1,8].
AMF stimulates cell motility and growth by binding to its
cell surface receptor, a glycoprotein of 78 kDa, referred to as
gp78 or AMF receptor (AMF-R) [9^11]. AMF-R is a seven-
transmembrane domain, pertussis toxin-sensitive G protein-
coupled receptor that has recently been identi¢ed as an E3
ubiquitin protein ligase [12,13]. AMF-R expression is associ-
ated with tumor motility and metastasis and signi¢cantly in-
creased in neoplastic tissue [14]. AMF-R is expressed in cer-
ebellar and hippocampal neurons and its activation may play
a role in neuronal plasticity during development and in mem-
ory and learning [15,16].
The fact that a glycolytic enzyme also exhibits cytokine
activity is intriguing and raises questions as to the relationship
between its enzymatic and cytokine activities. The crystal
structures of mammalian (rabbit, pig, human) and bacterial
(Bacillus stearothermophilus) PGI have been determined and
show that the active site of the functional homodimeric en-
zyme is conserved evolutionarily [17^22]. Inhibitors of PGI
activity prevent the motility stimulating activity of PGI
[1,7,23]. Furthermore, the bacterial form of the enzyme has
been reported to stimulate the motility of CT-26 mouse colon
tumor cells and this motility stimulation is sensitive to inhibi-
tion by the PGI inhibitor 5-phosphoarabinoate [17,19]. These
data support a role for the evolutionarily conserved enzymatic
site in receptor binding of PGI.
AMF-R internalizes its ligand via two pathways, a clathrin-
mediated pathway to multivesicular bodies (MVBs) and a
caveolae-mediated pathway to the endoplasmic reticulum
[24^26]. In order to address the nature of the interaction of
PGI with its receptor, we have used the clathrin-dependent
endocytosis of AMF-R as an assay for receptor binding
[25]. We report that bacterial PGI is not internalized by
NIH-3T3 cells and that neither bacterial nor yeast PGI com-
pete with mammalian PGI for receptor binding and internal-
ization. Furthermore, neither the bacterial nor yeast forms of
the enzyme are able to stimulate the motility of NIH-3T3
cells. These results demonstrate that the cytokine activity of
PGI is speci¢c to mammalian PGI and argue that the PGI
enzymatic site is not su⁄cient for receptor binding.
2. Materials and methods
2.1. Cells and reagents
NIH-3T3 ¢broblasts were as previously described [25]. Bacterial,
yeast and mammalian PGI were obtained from Sigma (Oakville,
ON, Canada). Bacterial and rabbit PGI were biotinylated with
NHS-LC-biotin (Pierce, Rockford, IL, USA) or rabbit PGI conju-
gated to Alexa-568 (Molecular Probes, Eugene, OR, USA) as per
the manufacturers’ instructions. Horseradish peroxidase and Texas
Red-conjugated streptavidin were purchased from Jackson Immuno-
research Laboratories (West Grove, PA, USA). Synthetic peptides
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corresponding to amino acids 1^10 (AALTRNPQFQ), 362^373
(YITKSGARVDHQ), 443^460 (EARKELQAAGKSPEDLEK), and
547^557 (FIKQQRDTKLE) of the mouse PGI sequence were pur-
chased from the NRC Biotechnology Research Institute (Montreal,
QC, Canada).
2.2. Immuno£uorescence labeling
Endocytosis of biotinylated or Alexa-568-conjugated PGI to MVBs
in NIH-3T3 cells was performed as previously described [25]. For the
competition assays, cells were pulsed for 30 min at 37‡C with labeled
PGI plus the indicated concentrations of unlabeled rabbit, bacteria or
yeast PGI or of selected synthetic peptides. Cells were washed and
¢xed, and biotinylated PGI revealed as described [25] and Alexa-568-
PGI visualized directly. After labeling, the coverslips were mounted in
Airvol (Air Products and Chemicals, Allentown, PA, USA) and
viewed with the 63U Zeiss Plan Apochromat objective, selective ¢lters
and a QImaging digital camera or with the 60U NikonPlan Apochro-
mat objective of a Bio-Rad MRC600 confocal microscope. To quan-
tify endocytosed biotinylated PGI, at least 10 ¢elds per experiment
were randomly selected from at least three experiments. The £uores-
cence intensity per cell was quanti¢ed using Northern Eclipse image
analysis software (Empix Imaging, Mississauga, ON, Canada). For all
values, control labeling in the absence of biotinylated PGI was sub-
tracted.
2.3. SDS^PAGE and immunoblotting
Protein concentration was measured using the BCA protein assay
(Pierce). One Wg of native or biotinylated PGI was separated by SDS^
PAGE and proteins revealed with Coomassie blue. Alternatively, the
gel was blotted to nitrocellulose membranes (Amersham) and biotinyl-
ated PGI detected with horseradish peroxidase-conjugated strepta-
vidin and chemiluminescence.
2.4. PGI enzymatic activity
PGI activity was assayed as previously described [27]. One ml of the
reaction mixture (50 mM triethanolamine bu¡er, pH 8.3, 1 mM
EDTA, 4 mM fructose 6-phosphate as a substrate, 0.5 mM NADP
and one unit of glucose 6-phosphate dehydrogenase) was preincu-
bated at 30‡C for 5 min in a 1 cm light quartz cuvette in the sample
compartment of a thermostatically regulated spectrophotometer
(UV160U, UV-Visible recording spectrophotometer, Shimadzu Co.).
The reaction was initiated by the addition of 80 ng of rabbit, bacteria
or yeast PGI. The rate of isomerization was monitored for 10 min and
determined from the linear reaction phase.
2.5. Phagokinetic track motility assay
NIH-3T3 cells were plated (2000 cells/35 mm dish) on glass cover-
slips coated with colloidal gold prepared as described [10]. After 24 h
incubation, the cells were ¢xed with 3% paraformaldehyde and the
phagokinetic tracks visualized using dark-¢eld illumination with the
10U objective of a Zeiss Axiovert inverted microscope equipped with
a Princeton MicroView CCD camera. The area cleared of gold par-
ticles by at least 100 cells was thresholded and measured using North-
ern Eclipse image analysis software (Empix Imaging).
3. Results
We have previously reported that commercial rabbit PGI/
AMF is internalized via both clathrin-dependent and clathrin-
independent pathways [24^26]. For this study, we have used
the clathrin-dependent endocytosis of biotinylated rabbit PGI
to MVBs to assess receptor binding and internalization [25]. It
Fig. 1. Bacterial PGI is not endocytosed by NIH-3T3 cells. NIH-3T3 cells were incubated for 30 min with 100 Wg/ml of mammalian biotinyl-
ated PGI (A) or bacterial biotinylated PGI (B) and after ¢xation, endocytosed biotinylated PGI was revealed with Texas Red streptavidin.
Only mammalian PGI can be detected within intracellular MVBs. SDS^PAGE analysis (C) of 1 Wg total protein revealed the presence of native
(3) and biotinylated (+) mammalian (M) and bacterial (B) PGI by Coomassie blue staining (left) and by horseradish peroxidase-streptavidin la-
beling (right).
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has been reported that the bacterial form of PGI stimulates
the motility of murine CT-26 cells [17,19] and we therefore
undertook to determine whether bacterial PGI recognizes
mammalian AMF-R and is internalized. As seen in Fig. 1A,
biotinylated rabbit PGI is endocytosed to MVBs in NIH-3T3
cells after a 30 min incubation at 37‡C while a similarly bio-
tinylated bacterial PGI is not detected within the cells (Fig.
1B). The bacterial form of the enzyme migrates slightly faster
than rabbit PGI and the biotinylated form of both enzymes is
detected by blot with streptavidin-horseradish peroxidase
(Fig. 1C).
Con¢rmation that receptor binding is speci¢c for the mam-
malian form of the enzyme was obtained by the ability of 500
Wg/ml unconjugated rabbit but not bacterial or yeast PGI to
compete with the endocytosis of biotinylated rabbit PGI to
MVBs (Fig. 2A^D). Increasing concentrations of unlabeled
rabbit PGI progressively compete with biotinylated rabbit
PGI for receptor binding and subsequent endocytosis to
MVBs such that at 500 Wg/ml essentially no internalized bio-
tinylated rabbit PGI is detected (Fig. 2B,E). The addition of
an excess of the yeast and bacterial forms of PGI partially
(6 30%) reduced the internalization of rabbit PGI (Fig. 2E).
The extent of the reduction did not increase with PGI con-
centration indicating that they are not competing directly with
mammalian PGI for binding to the cell surface PGI receptor
(gp78/AMF-R).
The isomerase activity of the bacterial, yeast and rabbit
enzymes was measured and all three commercial preparations
used exhibited signi¢cant levels of enzyme activity (Fig. 3A).
Indeed, isomerase activity of the bacterial and yeast prepara-
tions was superior to that of the rabbit enzyme. Addition of
1 Wg/ml of rabbit PGI to NIH-3T3 cells plated on colloidal
Fig. 2. Bacterial and yeast PGI do not compete with mammalian PGI for receptor binding and endocytosis. NIH-3T3 cells were incubated for
30 min with 15 Wg/ml mammalian biotinylated PGI in regular medium (A) or in regular medium supplemented with 500 Wg/ml mammalian (B),
bacterial (C) or yeast (D) PGI and after ¢xation, the endocytosis of biotinylated mammalian PGI was revealed with Texas Red streptavidin.
The endocytosis of biotinylated mammalian PGI in the presence of 60, 125, 250, and 500 Wg/ml bacterial (white), yeast (gray), and mammalian
(black) PGI was quanti¢ed (E) and is presented as the percent of endocytosis in the absence of unlabeled PGI ( U S.E.M.). Reduction in the en-
docytosis of biotinylated mammalian PGI was only observed with increasing concentrations of native mammalian PGI.
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gold coated cover slips increased their phagokinetic motility
by approximately twofold. Neither bacterial nor yeast PGI
induced NIH-3T3 motility (Fig. 3B).
The inability of the yeast and bacterial forms of PGI to
compete for binding to cell surface AMF-R and to stimulate
cell motility argues that regions of the mammalian PGI struc-
ture outside of the active site are implicated in its cytokine
activity [20]. Sequence comparison allowed us to identify re-
gions in the mammalian PGI sequence that show signi¢cant
di¡erences with not only bacterial PGI but also with yeast
PGI. We prepared synthetic peptides corresponding to the
most distinct sequences of the mammalian protein that were
localized to peripheral regions of the PGI structure [20]. These
included the N-terminal region (aa 1^10), the hook region (aa
443^460), and the C-terminal region (aa 547^557) as well as
the third loop region (aa 362^373) [20]. At concentrations up
to 1 mg/ml, none of the selected peptides competed with the
binding and endocytosis of rabbit PGI (Fig. 4).
4. Discussion
The demonstration here that neither bacterial nor yeast
PGI, that both express the highly conserved PGI active site,
are able to bind to the cell surface receptor for PGI nor
stimulate the motility of NIH-3T3 ¢broblasts argues that
the active site of this glycolytic enzyme is not su⁄cient for
receptor binding and does not exhibit a selective lectin func-
tion. Indeed, while gp78/AMF-R was originally identi¢ed for
its O-linked glycosylation [28,29], it is di⁄cult to imagine that
sugar binding alone can be receptor-speci¢c.
Our data con£ict with prior studies showing that bacterial
PGI can stimulate the motility of mouse CT-26 colon cancer
cells [17,19]. The basis for the discrepancy remains unclear
and could potentially be related to cell line to cell line di¡er-
ences. However, the inability of bacterial PGI to be endocy-
tosed, to compete with the endocytosis of mammalian PGI or
to stimulate the motility of NIH-3T3 ¢broblasts demonstrates
that it is not binding to the same receptor. Alternative recep-
tors for PGI have yet to be identi¢ed although it should be
noted that two a⁄nities for PGI cell surface binding have
been described and proposed to be related to the metastatic
potential of the cell lines studied [30]. Certainly, recent studies
describing PGI as an autoantigen on the endothelial cell sur-
face and on sperm suggest that PGI may recognize cell surface
molecules other than AMF-R [31,32]. It should also be noted
that following its internalization to MVBs PGI associates with
¢bronectin ¢brils, an association that is receptor-mediated but
that may potentially implicate distinct ¢bronectin recognition
sites [25].
The ability of inhibitors of the isomerase activity of PGI to
block its cytokine function [1,7,23] in the absence of signi¢-
cant conformational changes in the structure of the mamma-
lian enzyme in the presence of inhibitors [18,21,33,34] sup-
ports a role for the active site in its cytokine function. It
Fig. 3. Bacterial and yeast PGI preparations exhibit isomerase activ-
ity but do not stimulate the motility of NIH-3T3 ¢broblasts. (A)
The isomerase activity of bacterial (B, white), yeast (Y, gray), and
mammalian (M, black) PGI was measured and the three prepara-
tions exhibited signi¢cant activity. Minimal activity was detected in
the absence of PGI and was subtracted from the presented values.
(B) Using a phagokinetic track motility assay, the ability of 1 Wg/ml
bacterial (B, white), yeast (Y, gray), and mammalian (M, black)
PGI to stimulate the motility of NIH-3T3 cells relative to basal con-
trol motility in the absence of added PGI (C, striped) was mea-
sured. Increased motility was only detected for mammalian PGI.
Values presented represent the average ( U S.E.M.) of at least three
independent experiments.
Fig. 4. Select peptides corresponding to peripheral regions of mammalian PGI do not compete for receptor binding. NIH-3T3 cells were incu-
bated with 5 Wg/ml of Alexa-568-conjugated mammalian PGI for 30 min at 37‡C in the presence of 0, 250, 500 or 1000 Wg/ml of either unla-
beled mammalian PGI or peptides aa 1^10 (N-terminal), aa 362^373 (loop region), aa 443^460 (hook region), and aa 547^557 (C-terminal re-
gion) [20] of the mouse PGI sequence. Endocytosis of Alexa-568-conjugated mammalian PGI was quanti¢ed and is presented as the percent of
endocytosis in the absence of competitor. Each value represents the average ( U S.E.M.) of at least three independent experiments except for aa
1^10 and aa 362^373 at 250 Wg/ml (n=2).
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remains possible that subtle modi¢cation, below the resolu-
tion of the crystallographic methods used, of the structure of
peripheral PGI regions may disrupt receptor binding. The
partial inhibition by bacterial and yeast PGI of the endocy-
tosis of mammalian PGI (Fig. 2) may re£ect low a⁄nity bind-
ing to the receptor via the conserved binding site. Further-
more, while the inability of select peptides, corresponding to
distinct peripheral PGI regions [20], to inhibit PGI internal-
ization (Fig. 4) can be considered neither complete nor con-
clusive, it does support the idea that receptor binding domain
of PGI is a complex motif that may include elements of the
active site.
PGI is an example of a ‘moonlighting’ protein that exhibits
multiple cellular functions [35,36] and the data presented here
support the evolutionary acquisition of an additional cytokine
function for this glycolytic enzyme. Future studies of the re-
ceptor binding motifs of this protein should necessarily focus
not only on the active site but also on PGI domains that are
speci¢c to the mammalian form of the enzyme.
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